[1] Søe K, Delaisse JM, Borggaard XG, 2021, Osteoclast Formation at the Bone Marrow/Bone Surface Interface: Importance of Structural Elements, Matrix, and Intercellular Communication. Seminars in Cell & Developmental Biology, 112: 8–15.

[2] Chen EH, Grote E, Mohler W, et al., 2007, Cell-Cell Fusion. FEBS Letters, 581: 2181–2193.

[3] Xing L, Xiu Y, Boyce BF, 2012, Osteoclast Fusion and Regulation by RANKL-Dependent and Independent Factors. World Journal of Orthopedics, 3: 212–222.

[4] Kim K, Lee SH, Ha KJ, et al., 2008, NFATc1 Induces Osteoclast Fusion via Up-Regulation of Atp6v0d2 and the Dendritic Cell-Specific Transmembrane Protein (DC-STAMP). Molecular Endocrinology (Baltimore, Md.), 22: 176–185.

[5] Ishii M, Saeki Y, 2008, Osteoclast Cell Fusion: Mechanisms and Molecules. Modern Rheumatology, 18: 220–227.

[6] Krishnacoumar B, Stenzel M, Garibagaoglu H, et al., 2024, Caspase-8 Promotes Scramblase-Mediated Phosphatidylserine Exposure and Fusion of Osteoclast Precursors. Bone Research, 12: 40.

[7] Barnea-Zohar M, Stein M, Reuven N, et al., 2024, SNX10 Regulates Osteoclastogenic Cell Fusion and Osteoclast Size in Mice. J Bone Miner Res, 39: 1503–1517.

[8] Leikina E, Whitlock JM, Melikov K, et al., 2024, Formation of Multinucleated Osteoclasts Depends on an Oxidized Species of Cell Surface-Associated La Protein. eLife, 13.

[9] Gu R, Liu H, Hu M, et al., 2023, D-Mannose Prevents Bone Loss under Weightlessness. Journal of Translational Medicine, 21: 8.

[10] Wan Y, Nemoto YL, Oikawa T, et al., 2025, Mechanical Control of Osteoclast Fusion by Membrane-Cortex Attachment and BAR Proteins. The Journal of Cell Biology, 224.

[11] Whitlock JM, Leikina E, Melikov K, et al., 2023, Cell Surface-Bound La Protein Regulates the Cell Fusion Stage of Osteoclastogenesis. Nature Communications, 14: 616.

[12] Garcia-Hernandez ML, Rangel-Moreno J, Garcia-Castaneda M, et al., 2022, Dendritic Cell-Specific Transmembrane Protein Is Required for Synovitis and Bone Resorption in Inflammatory Arthritis. Front Immunol, 13: 1026574.

[13] Wang Q, Wang H, Yan H, et al., 2022, Suppression of Osteoclast Multinucleation via a Posttranscriptional Regulation-Based Spatiotemporally Selective Delivery System. Science Advances, 8: eabn3333.

[14] Kong X, Liu H, Chen S, et al., 2025, Bioengineered Bacterial Extracellular Vesicles for Targeted Delivery of an Osteoclastogenesis-Inhibitory Peptide to Alleviate Osteoporosis. Journal of Controlled Release: Official Journal of the Controlled Release Society, 382: 113751.

[15] Wang Q, Xie J, Zhou C, et al., 2022, Substrate Stiffness Regulates the Differentiation Profile and Functions of Osteoclasts via Cytoskeletal Arrangement. Cell Proliferation, 55: e13172.

[16] Li X, Jiang Y, Liu X, et al., 2023, Mesenchymal Stem Cell-Derived Apoptotic Bodies Alleviate Alveolar Bone Destruction by Regulating Osteoclast Differentiation and Function. International Journal of Oral Science, 15: 51.

[17] Yagi M, Miyamoto T, Sawatani Y, et al., 2005, DC-STAMP Is Essential for Cell-Cell Fusion in Osteoclasts and Foreign Body Giant Cells. The Journal of Experimental Medicine, 202: 345–351.

[18] Jansen BJ, Eleveld-Trancikova D, Sanecka A, et al., 2009, OS9 Interacts with DC-STAMP and Modulates Its Intracellular Localization in Response to TLR Ligation. Molecular Immunology, 46: 505–515.

[19] Moura SR, Sousa AB, Olesen JB, et al., 2024, Stage-Specific Modulation of Multinucleation, Fusion, and Resorption by the Long Non-Coding RNA DLEU1 and miR-16 in Human Primary Osteoclasts. Cell Death & Disease, 15: 741.

[20] van Duijn A, Van der Burg SH, Scheeren FA, 2022, CD47/SIRPα Axis: Bridging Innate and Adaptive Immunity. Journal for Immunotherapy of Cancer, 10.

[21] Chiu YH, Schwarz E, Li D, et al., 2017, Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Regulates Osteoclast Differentiation via the Ca(2+)/NFATc1 Axis. Journal of Cellular Physiology, 232: 2538–2549.

[22] Kim SC, Gu DR, Yang H, et al., 2025, Polysaccharides from Psoralea Corylifolia Seeds Suppress Osteoclastogenesis and Alleviate Osteoporosis. International Journal of Biological Macromolecules, 315: 144423.

[23] Liu T, Jiang L, Xiang Z, et al., 2022, Tereticornate A Suppresses RANKL-Induced Osteoclastogenesis via the Downregulation of c-Src and TRAF6 and the Inhibition of RANK Signaling Pathways. Biomedicine & Pharmacotherapy, 151: 113140.

[24] Zhu G, Chen W, Tang CY, et al., 2022, Knockout and Double Knockout of Cathepsin K and Mmp9 Reveals a Novel Function of Cathepsin K as a Regulator of Osteoclast Gene Expression and Bone Homeostasis. International Journal of Biological Sciences, 18: 5522–5538.

[25] Xu W, Chao R, Xie X, et al., 2024, IL13Ralpha2 as a Crucial Receptor for Chi3l1 in Osteoclast Differentiation and Bone Resorption through the MAPK/AKT Pathway. Cell Communication and Signaling: CCS, 22: 81.

[26] Sviercz FA, Jarmoluk P, Cevallos CG, et al., 2023, Massively HIV-1-Infected Macrophages Exhibit a Severely Hampered Ability to Differentiate into Osteoclasts. Front Immunol, 14: 1206099.

[27] Li Y, Yang JY, Lin ML, et al., 2025, ACT001 Improves OVX-Induced Osteoporosis by Suppressing the NF-kappaB/NLRP3 Signaling Pathway. Molecular Medicine (Cambridge, Mass.), 31: 131.

[28] Qu T, Li B, Wang Y, 2022, Targeting CD47/SIRPalpha as a Therapeutic Strategy, Where We Are and Where We Are Headed. Biomarker Research, 10: 20.

[29] Chen F, Tian L, Pu X, et al., 2022, Enhanced Ectopic Bone Formation by Strontium-Substituted Calcium Phosphate Ceramics through Regulation of Osteoclastogenesis and Osteoblastogenesis. Biomaterials Science, 10: 5925–5937.

[30] Sviercz F, Jarmoluk P, Godoy Coto J, et al., 2024, The Abortive SARS-CoV-2 Infection of Osteoclast Precursors Promotes Their Differentiation into Osteoclasts. Journal of Medical Virology, 96: e29597.

[31] Wolin SL, Cedervall T, 2002, The La Protein. Annual Review of Biochemistry, 71: 375–403.

[32] Sims NA, Walsh NC, 2012, Intercellular Cross-Talk among Bone Cells: New Factors and Pathways. Current Osteoporosis Reports, 10: 109–117.

[33] van Duijn A, Van der Burg SH, Scheeren FA, 2022, CD47/SIRPα Axis: Bridging Innate and Adaptive Immunity. Journal for Immunotherapy of Cancer, 10.

[34] Zheng J, He W, Chen Y, et al., 2025, Erianin Serves as an NFATc1 Inhibitor to Prevent Breast Cancer-Induced Osteoclastogenesis and Bone Destruction. Journal of Advanced Research, 69: 399–411.

[35] Logtenberg MEW, Scheeren FA, Schumacher TN, 2020, The CD47-SIRPα Immune Checkpoint. Immunity, 52: 742–752.

[36] Zhu D, Hadjivassiliou H, Jennings C, et al., 2024, CC-96673 (BMS-986358), an Affinity-Tuned Anti-CD47 and CD20 Bispecific Antibody with Fully Functional Fc, Selectively Targets and Depletes Non-Hodgkin's Lymphoma. mAbs, 16: 2310248.

[37] Xu Y, Song D, Lin X, et al., 2023, Corylifol A Protects against Ovariectomized-Induced Bone Loss and Attenuates RANKL-Induced Osteoclastogenesis via ROS Reduction, ERK Inhibition, and NFATc1 Activation. Free Radical Biology & Medicine, 196: 121–132.

[38] van Helden MJ, Zwarthoff SA, Arends RJ, et al., 2023, BYON4228 Is a Pan-Allelic Antagonistic SIRPalpha Antibody That Potentiates Destruction of Antibody-Opsonized Tumor Cells and Lacks Binding to SIRPgamma on T Cells. Journal for Immunotherapy of Cancer, 11: 1–12.

[39] Cendrowicz E, Jacob L, Greenwald S, et al., 2022, DSP107 Combines Inhibition of CD47/SIRPalpha Axis With Activation of 4-1BB to Trigger Anticancer Immunity. Journal of Experimental & Clinical Cancer Research: CR, 41: 97.

[40] Bae S, Kim K, Kang K, et al., 2023, RANKL-Responsive Epigenetic Mechanism Reprograms Macrophages Into Bone-Resorbing Osteoclasts. Cellular & Molecular Immunology, 20: 94–109.

[41] Sheng M, Lin Y, Xu D, et al., 2021, CD47-Mediated Hedgehog/SMO/GLI1 Signaling Promotes Mesenchymal Stem Cell Immunomodulation in Mouse Liver Inflammation. Hepatology (Baltimore, Md.), 74: 1560–1577.

[42] Han X, Sterling H, Chen Y, et al., 2000, CD47, a Ligand for the Macrophage Fusion Receptor, Participates in Macrophage Multinucleation. The Journal of Biological Chemistry, 275: 37984–37992.

[43] Maile LA, DeMambro VE, Wai C, et al., 2011, An Essential Role for the Association of CD47 to SHPS-1 in Skeletal Remodeling. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 26: 2068–2081.

[44] Uluçkan O, Becker SN, Deng H, et al., 2009, CD47 Regulates Bone Mass and Tumor Metastasis to Bone. Cancer Research, 69: 3196–3204.

[45] Lundberg P, Koskinen C, Baldock PA, et al., 2007, Osteoclast Formation Is Strongly Reduced Both in Vivo and in Vitro in the Absence of CD47/SIRPalpha-Interaction. Biochemical and Biophysical Research Communications, 352: 444–448.

[46] Møller AM, Delaissé JM, Søe K, 2017, Osteoclast Fusion: Time-Lapse Reveals Involvement of CD47 and Syncytin-1 at Different Stages of Nuclearity. Journal of Cellular Physiology, 232: 1396–1403.

[47] Hobolt-Pedersen AS, Delaissé JM, Søe K, 2014, Osteoclast Fusion Is Based on Heterogeneity Between Fusion Partners. Calcif Tissue Int, 95: 73–82.

[48] Zheng H, Liu Y, Deng Y, et al., 2024, Recent Advances of NFATc1 in Rheumatoid Arthritis-Related Bone Destruction: Mechanisms and Potential Therapeutic Targets. Molecular Medicine (Cambridge, Mass.), 30: 20.

[49] Che Z, Wang W, Zhang L, et al., 2025, Therapeutic Strategies Targeting CD47-SIRPalpha Signaling Pathway in Gastrointestinal Cancers Treatment. Journal of Pharmaceutical Analysis, 15: 101099.

[50] Biedermann A, Patra-Kneuer M, Mougiakakos D, et al., 2024, Blockade of the CD47/SIRPalpha Checkpoint Axis Potentiates the Macrophage-Mediated Antitumor Efficacy of Tafasitamab. Haematologica, 109: 3928–3940.

[51] Luo N, Zhang L, Xiu C, et al., 2024, Piperlongumine, a Piper Longum-Derived Amide Alkaloid, Protects Mice From Ovariectomy-Induced Osteoporosis by Inhibiting Osteoclastogenesis via Suppression of p38 and JNK Signaling. Food & Function, 15: 2154–2169.

[52] Gal M, Kim O, Tran PT, et al., 2022, Mussaendoside O, a N-Triterpene Cycloartane Saponin, Attenuates RANKL-Induced Osteoclastogenesis and Inhibits Lipopolysaccharide-Induced Bone Loss. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology, 105: 154378.

[53] Groetsch B, Schachtschabel E, Tripal P, et al., 2022, Inflammatory Activation of the FcgammaR and IFNgammaR Pathways Co-Influences the Differentiation and Activity of Osteoclasts. Front Immunol, 13: 958974.

[54] Kim H, Takegahara N, Choi Y, 2023, IgSF11-Mediated Phosphorylation of Pyruvate Kinase M2 Regulates Osteoclast Differentiation and Prevents Pathological Bone Loss. Bone Research, 11: 17.

[55] Dou C, Zhen G, Dan Y, et al., 2022, Sialylation of TLR2 Initiates Osteoclast Fusion. Bone Research, 10: 24.

[56] Leikina E, Tsaturyan AK, Melikov K, et al., 2025, Phosphatidylserine Exposure and Extracellular Annexin A5 Weaken the Actin Cortex in Osteoclast Fusion. bioRxiv: The Preprint Server for Biology, 1–12.

[57] Li YN, Chen CW, Trinh-Minh T, et al., 2022, Dynamic Changes in O-GlcNAcylation Regulate Osteoclast Differentiation and Bone Loss via Nucleoporin 153. Bone Research, 10: 51.

[58] Kim H, Lee K, Kim JM, et al., 2021, Selenoprotein W Ensures Physiological Bone Remodeling by Preventing Hyperactivity of Osteoclasts. Nature Communications, 12: 2258.

[59] Zhang JQ, Takahashi A, Gu JY, et al., 2021, In Vitro and In Vivo Detection of Tunneling Nanotubes in Normal and Pathological Osteoclastogenesis Involving Osteoclast Fusion. Laboratory Investigation: A Journal of Technical Methods and Pathology, 101: 1571–1584.

[60] Ma Y, Shi X, Zhao H, et al., 2022, Potential Mechanisms of Osteoprotegerin-Induced Damage to Osteoclast Adhesion Structures via P2X7R-Mediated MAPK Signaling. International Journal of Molecular Medicine, 49: 1–12.

[61] Kukita T, Hiura H, Gu JY, et al., 2021, Modulation of Osteoclastogenesis through Adrenomedullin Receptors on Osteoclast Precursors: Initiation of Differentiation by Asymmetric Cell Division. Laboratory Investigation, 101: 1449–1457.

[62] Hasegawa T, Ishii M, 2022, Pathological Osteoclasts and Precursor Macrophages in Inflammatory Arthritis. Frontiers in Immunology, 13: 867368.

[63] Zhang W, Noller K, Crane J, et al., 2023, RANK(+)TLR2(+) Myeloid Subpopulation Converts Autoimmune to Joint Destruction in Rheumatoid Arthritis. eLife, 12: e85553.

[64] Das A, Saeki K, Dell'Orso S, et al., 2025, Integrative Single-Cell RNA-Seq and ATAC-Seq Identifies Transcriptional and Epigenetic Blueprint Guiding Osteoclastogenic Trajectory. Journal of Bone and Mineral Research, 40: 1127–1143.

[65] Zhang Y, Sun H, Huang F, et al., 2024, The Chromatin Remodeling Factor Arid1a Cooperates with Jun/Fos to Promote Osteoclastogenesis by Epigenetically Upregulating Siglec15 Expression. Journal of Bone and Mineral Research, 39: 775–790.

[66] Liao R, Dewey MJ, Rong J, et al., 2024, Matrix-Bound Nanovesicles Alleviate Particulate-Induced Periprosthetic Osteolysis. Science Advances, 10: eadn1852.

[67] Ma J, Zhu L, Zhou Z, et al., 2021, The Calcium Channel TRPV6 Is a Novel Regulator of RANKL-Induced Osteoclastic Differentiation and Bone Absorption Activity through the IGF-PI3K-AKT Pathway. Cell Proliferation, 54: e12955.

[68] Wu J, Zhang B, Du W, et al., 2025, OC-STAMP Is a Potential Biomarker and Therapeutic Target for Silicosis: An Exploratory Investigation. Journal of Translational Medicine, 23: 214.

[69] Tsukasaki M, Huynh NC, Okamoto K, et al., 2020, Stepwise Cell Fate Decision Pathways during Osteoclastogenesis at Single-Cell Resolution. Nature Metabolism, 2: 1382–1390.

[70] Okusha Y, Tran MT, Itagaki M, et al., 2020, Rab11A Functions as a Negative Regulator of Osteoclastogenesis through Dictating Lysosome-Induced Proteolysis of c-Fms and RANK Surface Receptors. Cells, 9: –.

[71] Jagannatha P, Tankka AT, Lorenz DA, et al., 2024, Long-Read Ribo-STAMP Simultaneously Measures Transcription and Translation with Isoform Resolution. Genome Research, 34: 2012–2024.

[72] Zhu L, Tang Y, Li XY, et al., 2023, A Zeb1/MtCK1 Metabolic Axis Controls Osteoclast Activation and Skeletal Remodeling. The EMBO Journal, 42: e111148.

[73] Ha MT, Tran PT, Tran HNK, et al., 2021, Anti-Osteoclastogenic Effects of Indole Alkaloids Isolated from Barley (Hordeum Vulgare Var. Hexastichon) Grass. Journal of Agricultural and Food Chemistry, 69: 12994–13005.